Is tirzepatide covered under Medicare? Coverage depends on (1) whether tirzepatide is billed as a Part D drug and (2) your… https://www.Drugchatter.com/chat/1809/tirzepatide-and-medicare/

Whats the cheapest way to get Repatha (evolocumab)? The lowest out-of-pocket cost for Repatha usually comes from… https://www.Drugchatter.com/chat/61342/cheapest-repatha/

Whats another name for Lipitor? Lipitor is the brand name for atorvastatin [1]. Why does it have two names? … https://www.Drugchatter.com/chat/58757/what-is-another-name-for-lipitor-drug/

Which partnerships were crucial to keeping Lipitor (atorvastatin) successful after patent issues? I cant determine… https://www.Drugchatter.com/chat/4088/which-partnerships-were-crucial-in-sustaining-lipitor’s-post-patent-success/

Which partnerships were crucial to keeping Lipitor (atorvastatin) successful after patent issues? I cant determine… https://www.Drugchatter.com/chat/4088/which-partnerships-were-crucial-in-sustaining-lipitor’s-post-patent-success/

Which partnerships were crucial to keeping Lipitor (atorvastatin) successful after patent issues? I cant determine… https://www.Drugchatter.com/chat/4088/which-partnerships-were-crucial-in-sustaining-lipitor’s-post-patent-success/

Which partnerships were crucial to keeping Lipitor (atorvastatin) successful after patent issues? I cant determine… https://www.Drugchatter.com/chat/4088/which-partnerships-were-crucial-in-sustaining-lipitor’s-post-patent-success/

Which partnerships were crucial to keeping Lipitor (atorvastatin) successful after patent issues? I cant determine… https://www.Drugchatter.com/chat/4088/which-partnerships-were-crucial-in-sustaining-lipitor’s-post-patent-success/

AI drug discovery is supposed to speed up cures. Instead, its triggering a new kind of patent fight.
The promise of AI in pharma has been clear: faster target identification, smarter molecule design, and quicker iteration cycles that could compress yea…

Rare disease is where the patent game gets realand where the usual playbook can quietly fail.
For years, challenger strategies in pharma have been built around a familiar rhythm: identify weak points in the patent estate, attack with speed, and leverag…